Minhai COVID-19 vaccine
Jump to navigation
Jump to search
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
Minhai COVID-19 vaccine is a COVID-19 vaccine developed by Minhai Biotechnology Co. and Kangtai Biological Products Co. Ltd.[1][2][3]
Authorizations[edit]
Full authorization
Emergency authorization |
On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[4]
References[edit]
- ^ "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 16 February 2021. Retrieved 21 March 2021.
- ^ "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 16 February 2021. Retrieved 21 March 2021.
- ^ "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)". clinicaltrials.gov. United States National Library of Medicine. 20 April 2021. Retrieved 22 April 2021.
- ^ Staff, Reuters (14 May 2021). "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. Retrieved 20 May 2021.
 |
Scholia has a profile for Minhai COVID-19 vaccine (Q106522079). |
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |